Gilead Sciences, Inc. (NASDAQ:GILD) – Jefferies Financial Group raised their FY2022 earnings per share (EPS) estimates for shares of Gilead Sciences in a research report issued to clients and investors on Monday, July 13th. Jefferies Financial Group analyst M. Yee now anticipates that the biopharmaceutical company will earn $6.32 per share for the year, up from their prior forecast of $6.27. Jefferies Financial Group has a “Buy” rating and a $97.00 price objective on the stock. Jefferies Financial Group also issued estimates for Gilead Sciences’ FY2023 earnings at $6.44 EPS.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.57 by $0.11. The business had revenue of $5.55 billion during the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The business’s revenue was up 5.1% on a year-over-year basis. During the same period last year, the business earned $1.67 EPS.
GILD has been the subject of a number of other reports. Cfra raised their price target on shares of Gilead Sciences from $71.00 to $74.00 and gave the company a “sell” rating in a report on Wednesday, April 29th. Cowen reaffirmed a “buy” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Monday, April 13th. Cantor Fitzgerald raised their price target on shares of Gilead Sciences from $78.00 to $86.00 and gave the company an “overweight” rating in a report on Tuesday, April 7th. Piper Sandler reaffirmed a “buy” rating and set a $90.00 price target on shares of Gilead Sciences in a report on Monday, June 8th. Finally, DZ Bank reissued a “buy” rating on shares of Gilead Sciences in a report on Monday, June 15th. Five analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $79.77.
GILD opened at $76.65 on Thursday. The company has a fifty day simple moving average of $75.71 and a 200 day simple moving average of $72.76. The firm has a market cap of $96.83 billion, a price-to-earnings ratio of 19.70, a PEG ratio of 3.36 and a beta of 0.70. Gilead Sciences has a twelve month low of $60.89 and a twelve month high of $85.97. The company has a current ratio of 3.04, a quick ratio of 2.92 and a debt-to-equity ratio of 1.00.
Large investors have recently modified their holdings of the stock. Guggenheim Capital LLC lifted its position in Gilead Sciences by 9.3% in the 4th quarter. Guggenheim Capital LLC now owns 917,971 shares of the biopharmaceutical company’s stock valued at $59,650,000 after purchasing an additional 78,152 shares during the last quarter. B. Riley Wealth Management Inc. increased its stake in Gilead Sciences by 19.7% during the 4th quarter. B. Riley Wealth Management Inc. now owns 9,101 shares of the biopharmaceutical company’s stock valued at $591,000 after buying an additional 1,496 shares during the period. Sontag Advisory LLC increased its stake in Gilead Sciences by 237.4% during the 1st quarter. Sontag Advisory LLC now owns 17,971 shares of the biopharmaceutical company’s stock valued at $1,344,000 after buying an additional 12,644 shares during the period. Country Club Trust Company n.a. acquired a new position in Gilead Sciences during the 1st quarter valued at about $224,000. Finally, Commerzbank Aktiengesellschaft FI increased its stake in Gilead Sciences by 1.3% during the 1st quarter. Commerzbank Aktiengesellschaft FI now owns 198,441 shares of the biopharmaceutical company’s stock valued at $14,835,000 after buying an additional 2,557 shares during the period. Hedge funds and other institutional investors own 78.74% of the company’s stock.
In related news, Director John Francis Cogan sold 2,413 shares of Gilead Sciences stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $79.90, for a total value of $192,798.70. Following the sale, the director now directly owns 57,273 shares in the company, valued at approximately $4,576,112.70. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Brett A. Pletcher sold 13,210 shares of Gilead Sciences stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the completion of the sale, the executive vice president now owns 27,204 shares in the company, valued at $2,155,372.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,905 shares of company stock worth $2,633,707. Insiders own 0.13% of the company’s stock.
The firm also recently declared a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Friday, June 12th were given a $0.68 dividend. The ex-dividend date was Thursday, June 11th. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.55%. Gilead Sciences’s payout ratio is currently 44.30%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: Investing strategies using the yield curve
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.